InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (6 ops.)
Insider track record
OtherDisclosed buys
1
Disclosed sells
6
T+90 hit rate
100%
T+90 mean return
+18.7%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Edwards Larry Todd, See Remarks. Insider active across 2 companies, notably Arcutis Biotherapeutics, Inc.. In total, 13 reports have been recorded. Breakdown: 1 buy · 6 sells. Total volume traded: €915k. Activity tracked since 27 September 2023. The latest transaction was filed on 24 August 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Edwards Larry Todd
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations13 total
100,000 shares0Common StockSEC:0000907654-26-000084:0
30,000 shares0Common StockSEC:0001628280-26-014328:0
2,052 shares@ US$25.49844.8% of flowCommon StockSEC:0001628280-26-005566:0
29,131 shares@ US$25.159767.7% of flowCommon StockSEC:0001994805-25-000008:0
4,207 shares@ US$19.98850.0027% mcap50.0% of flowCommon StockSEC:0001994805-25-000005:0
7,451 shares@ US$14.07199.9% of flowCommon StockSEC:0002065881-25-000009:0
38,000 shares0Common StockSEC:0001787306-25-000039:0
2,173 shares@ US$12.702.9% of flowCommon StockSEC:0001787306-25-000013:0
1,093 shares@ US$7.1060.8% of flowCommon StockSEC:0001787306-24-000169:0
Canonical exit: 28 Feb 2025 (T+90)
3,725 shares@ US$10.01223.6% of flowCommon StockSEC:0001787306-24-000136:0
60,000 shares0Common StockSEC:0001787306-24-000081:0
28,000 shares0Common StockSEC:0001787306-24-000010:0
60,000 shares0Common StockSEC:0001787306-23-000113:0
13 of 13 declarations
About Edwards Larry Todd
Edwards Larry Todd has 12 filings in total, all observed in the recent sample from 2023-10-03 to 2026-03-03. The buy and sell amounts in that sample are EUR 7353 and EUR 907407, the modal transaction nature is Sale, and the filings concern Arcutis Biotherapeutics, Inc.
